4346-s Orexin-A (Human)

Code:
4346-s
Name:
Orexin-A (Human)
Pyr-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2 (Disulfide bonds between Cys6-Cys12 and Cys7-Cys14)
(M.W. 3561.1) C152H243N47O44S4
Appetite-Boosting Peptide/Sleep-Wakefulness State Regulator
Package Price(Yen)
Vial 0.1 mg 22,000

main

Purity:
≧99.0% (HPLC)
Other Name:
Orexin A (human, bovine, canine, mouse, ovine, porcine, rat)
Hypocretin-1 (human, bovine, canine, mouse, ovine, porcine, rat)
オレキシンA ヒト, ラット, マウス
ヒポクレチン1
Storage:
-20 ℃
Source:
Rat, Mouse, Bovine
Production:
Synthetic Product

Solubility: H2O (0.1 mM)

more information

CAS Registry Number:
205640-90-0
Category:
Biologically Active Peptides

reference

  1. T. Sakurai, A. Amemiya, M. Ishii, I. Matsuzaki, R.M. Chemelli, H. Tanaka, S.C. Williams, J.A. Richardson, G.P. Kozlowski, S. Wilson, J.R.S. Arch, R.E. Buckingham, A.C. Haynes, S.A. Carr, R.S. Annan, D.E. McNulty, W.-S. Liu, J.A. Terrett, N.A. Elshourbagy, D.J. Bergsma, and M. Yanagisawa, Cell, 92, 573 (1998). (Original)
  2. L. de Lecea, T.S. Kilduff, C. Peyron, X.-B. Gao, P.E. Foye, P.E. Danielson, C. Fukuhara, E.L.F. Battenberg, V.T. Gautvik, F.S. Bartlett II, W.N. Frankel, A.N. van den Pol, F.E. Bloom, K.M. Gautvik, and J.G. Sutcliffe, Proc. Natl. Acad. Sci. USA, 95, 322 (1998). (cDNA; Same Sequence [Hypocretin])
  3. N. Takahashi, T. Okumura, H. Yamada, and Y. Kohgo, Biochem. Biophys. Res. Commun., 254, 623 (1999). (Pharmacol.)
  4. T. Ida, K. Nakahara, T. Murakami, R. Hanada, M. Nakazato, and N. Murakami, Biochem. Biophys. Res. Commun., 270, 318 (2000). (Pharmacol.)
  5. T. Sakurai, Regul. Pept., 85, 25 (1999). (Review)
  6. J.M. Siegel, Cell, 98, 409 (1999). (Review)
  7. L. De Lecea and J.G. Sutcliffe, Cell. Mol. Life Sci., 56, 473 (1999). (Review)
  8. R.J. Rodgers, Y. Ishii, J.C.G. Halford, and J.E. Blundell,, Neuropeptides, 36, 303 (2002). (Review)
  9. N. Tsujino and T. Sakurai, Pharmacol. Rev., 61, 162 (2009). (Review)
  10. M. Mieda and T. Sakurai, CNS Neurol. Disord. Drug Targets, 8, 281 (2009). (Review)